Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IVX-A12 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| IVX-A12 | BIOLOGICAL | IVX-A12 IM injection. |
| Licensed RSV Vaccine | BIOLOGICAL | Licensed RSV Vaccine (AREXVY) IM injection. |
| Placebo | BIOLOGICAL | Diluent |
IVX-A12 is an investigational monoclonal antibody developed by AstraZeneca PLC. It has been studied in Phase 2 clinical trials involving healthy adult participants, including a study in adults aged 60 to 85 years. The specific disease indication for IVX-A12 has not been publicly disclosed.
IVX-A12 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is the sponsor behind the clinical program evaluating the monoclonal antibody in healthy volunteer studies.
IVX-A12 is in Phase 2 clinical development. Two Phase 2 trials have been conducted, and both are listed as completed. The drug remains investigational and has not been approved by the FDA.
IVX-A12 has been evaluated in two completed Phase 2 trials. NCT05903183 studied the safety and immunogenicity of IVX-A12 in participants aged 60 to 85 years and enrolled 264 people. NCT06481579 studied IVX-A12 in adult participants and enrolled 143 people. Together the trials enrolled 407 participants.
IVX-A12 has been studied in healthy adult participants, including older adults aged 60 to 85 years, with a focus on safety and immunogenicity. The specific disease or condition it is intended to prevent or treat has not been publicly disclosed.